Conavi Medical Corp. (formerly Titan Medical Inc.) — Cyborg Score 4/10
Mixed
Medical Devices & Equipment - Robotic Surgery & Interventional Cardiology
Strategic Profile
The combined entity positions itself at the intersection of surgical robotics and interventional cardiology. Titan brought an expansive patent portfolio for RAS enhancement, while Conavi contributed a commercialized product with FDA 510(k) clearance and international regulatory approvals. The merger reflects a shift from pure R&D toward revenue-generating medical device operations.
Cyborg Score Rationale
The company has strong IP assets in robotic surgery and completed a meaningful strategic merger, but faces challenges including exchange downgrade (TSX to TSXV), limited near-term revenue visibility, and highly dilutive capital raises. The Conavi acquisition adds commercialized products but integration risks and market execution remain uncertain.
Top Insights
Completed reverse takeover merger with Conavi Medical (October 2024), combining robotic surgery IP with FDA-approved cardiovascular imaging technology
Delisted from TSX and moved to TSX Venture Exchange due to inability to maintain TSX listing requirements post-merger
Conavi's Novasight Hybrid System has FDA 510(k) clearance and regulatory approval in Canada, China, and Japan—a rare revenue-generating asset in the combined portfolio
Company completed aggressive capital raise (US$7.7M) in Q4 2024 to fund post-merger integration and commercialization efforts
Named Competitors
da Vinci Surgical System — Multi-armed robotic surgical platform with broad surgical applications
Medtronic Surgical Robotics — Robotic-assisted surgical systems for minimally invasive procedures
Novasight Hybrid System — FDA-cleared IVUS/OCT hybrid imaging for coronary interventions
Recent Developments
(October 2024) Completed business combination with Conavi Medical Inc.; delisted from TSX; renamed to Conavi Medical Corp.; applied for TSXV listing
(October 2024) Closed Conavi private placement of subscription receipts for gross proceeds of US$7.7 million
(April 2024) Announced planned merger with Conavi Medical Inc. in all-stock transaction
(March 2024) Entered definitive amalgamation agreement with Conavi Medical Inc.
Open the full interactive Conavi Medical Corp. (formerly Titan Medical Inc.) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.